Gland Pharma Ltd
Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
Strengths
- +Company has reduced debt.
- +Company is almost debt free.
- +Company has been maintaining a healthy dividend payout of 28.0%
Weaknesses
- −The company has delivered a poor sales growth of 5.62% over past five years.
- −Company has a low return on equity of 12.3% over last 3 years.
- −Promoter holding has decreased over last 3 years: -6.03%
Shareholding Pattern
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% |
| FIIs | 6.88% | 4.48%▼2.4 | 5.04%▲0.6 | 6.9%▲1.9 | 7.39%▲0.5 | 7.9%▲0.5 | 7.58%▼0.3 | 7.29%▼0.3 |
| DIIs | 32.83% | 35.37%▲2.5 | 34.8%▼0.6 | 33.27%▼1.5 | 32.86%▼0.4 | 32.63%▼0.2 | 32.99%▲0.4 | 33.36%▲0.4 |
| Public | 8.46% | 8.33%▼0.1 | 8.33% | 8%▼0.3 | 7.93%▼0.1 | 7.63%▼0.3 | 7.62%▼0.0 | 7.52%▼0.1 |
Financial Statements
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,098 | 1,175 | 1,012 | 1,063 | 1,011 | 1,030 | 1,039 | 1,074 | 1,178 | 1,262 |
| Expenses | 728 | 742 | 718 | 699 | 620 | 636 | 680 | 699 | 756 | 754 |
| Operating Profit | 369 | 433 | 294 | 364 | 391 | 394 | 359 | 375 | 422 | 508 |
| OPM % | 34% | 37% | 29% | 34% | 39% | 38% | 35% | 35% | 36% | 40% |
| Net Profit | 277 | 321 | 223 | 282 | 295 | 290 | 269 | 302 | 308 | 420 |
| EPS ₹ | 16.81 | 19.51 | 13.53 | 17.1 | 17.91 | 17.6 | 16.34 | 18.33 | 18.69 | 25.52 |
AI Insights
Mar 2026 revenue at ₹4,552Cr, up 10.6% YoY. OPM at 37%.
Borrowings at ₹3Cr. Debt-to-equity ratio: 0.00x. Healthy balance sheet.
CWIP at ₹138Cr (8% of fixed assets). Moderate ongoing capital expenditure.
DIIs: 33.36% (+9.98pp change). FIIs: 7.29% (+4.49pp change). Promoters hold 51.83%.
ROCE declining from 22% (Mar 2015) to 17% (Mar 2026). Working capital days: 209.
PE 26.6x with 17.4% ROCE. Price is 225% above book value of ₹656. Dividend yield: 0.83%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 1d
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 2d - Q4 and FY26 earnings call held on May 15, 2026; audio recording uploaded on website.
- Grant Of Stock Options Under Gland Pharma Employee Stock Option Scheme 2025 2d - Gland Pharma granted 690,019 ESOP 2025 options to 124 employees on May 15, 2026.
- The 48Th AGM Of The Company Will Be Held On August 25, 2026 2d
- Board Fixes Record Date Of August 11, 2026 For The Final Dividend 2d
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse